Bayer starts work on $43M+ expansion of OTC manufacturing site in Pennsylvania
German pharma giant Bayer will be looking to make a significant investment into one of its US plants that produces over-the-counter drugs.
Bayer announced that it will spend $43.6 million to expand its facility in Myerstown, PA, a small town east of Harrisburg. Bayer plans to increase the site by 70,000 square feet and will have room for the installation of eight packaging lines and an area to install rooftop solar panels. The project is expected to be completed by 2025 and will add around 50 to 75 jobs.
Much of Bayer’s OTC profile comes from the Myerstown facility, including brands such as Claritin, Midol, Alka-Seltzer and numerous other products, manufacturing a total of 14.1 billion tablets and 3.9 million liquid liters in 2021. The site is spread over 68 acres with over half a million square feet and employs over 630 people.
Toward the beginning of the year, Bayer said that it was planning to invest more than $2.26 billion into its pharmaceutical manufacturing apparatus over the next three years by expanding facilities in the US and Europe. The Big Pharma also plans to modernize and streamline processes at the facility.
Bayer will invest more than $2.26 billion in its pharmaceutical manufacturing over the next three years, as it looks to expand sites both in Europe and the US.
Other manufacturers have also been making significant investments in Pennsylvania this year.
West Pharmaceutical Services, a maker of vials, pre-fillable syringes and self-injection products, will invest $65 million to expand its manufacturing site in the town of Jersey Shore, PA a few miles down the road from Williamsport, PA. West is also planning to increase its headcount at its HQ in Exton, PA.
The Almac Group, a global contracting and manufacturing company for APIs and pharmaceuticals, is also expanding its North American headquarters in the town of Souderton, PA, northwest of Philadelphia with the same $65 million investment.
And in the western part of the state, ElevateBio and the University of Pittsburgh say they’ve signed a 30-year deal for ElevateBio to manufacture cell and gene therapies in Pittsburgh. The agreement will have ElevateBio locate its BaseCamp and GMP manufacturing facilities in the city, with the site eventually running gene editing, induced pluripotent stem cell (iPSC) and cell, vector and protein engineering efforts.